#EULAR2023 #POS1133 Consistent with clinical response in Phase 2 RCT, therapy with Updacitinib alone and ABV599-HD (Elsubrutinib + Upadacitinib) modulated IFN-I signalling pathways (IFN gene expression & proteomics). Assuring therapeutic evidence @RheumNowNews https://t.co/27mtCNg76X